← DiscoverAI PREDICTION · 3-MONTH VIEW
NA
NAMS
XNASNewAmsterdam Pharma Company N.V.
Mkt Cap $3.4BPHARMACEUTICAL PREPARATIONS
FUNDAMENTALS
P/S
172.47EV/EBITDA
-15.98P/B
5.85EPS (TTM)
$-1.82ROE
-32.0%ROA
-29.0%FCF
$-142.2MMKT CAP
$3.9BTECHNICAL ANALYSIS
Leaning Bearish
RSI-14
38.8
Neutral
MACD
0.000
Neutral
SMA-50
$-1.00
$-1.00
SMA-200
$-1.00
$-1.00
BOLL %B
0.35
Within bands
ATR-14
$1.81
RVOL
0.97x
Normal
MOMENTUM
-10.7%
10d -5.6% / 30d +0.6%
▲Edge over the market
NAMS holds a similar standing over 1 and 3 months.
WHERE IT RANKS · vs 2,129 names
20-DAY
▲#16
60-DAY
▲Top 15%#316
TYPICAL 3-MO RANGE · vs S&P 500
+0.1%leans upper+1.1%
▸ Horizon detail
20d#16
60dTop 15%
1y+analyst mean$52.24+63.8%
⚡ AI INSIGHT
Our model reads NAMS as strong both near-term and over the next few months. Analysts agree (91% Buy) — the bull case lines up.
RECENT CATALYSTS
- ANALYST_ACTIONSRBC Capital main4d
- NEWSPresentations at NLA 2026 Scientific Sessions42d
- NEWSParticipation at investor conferences in June48d
REVENUE & GROWTH
$3M
Revenue
+94.0%
QoQ
+0.0%
YoY
Gross Margin
1.0%Stable
ANALYST CONSENSUS
91% Buy
20 Buy2 Hold0 Sell
Low
$38
Mean
$52
High
$63
SHORT & FLOAT
Free Float
53.2%
6.9 days to cover.
Latest Headlines
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo7/2/2026
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
Yahoo7/1/2026
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51
Benzinga6/30/2026